Carvedilol is a potent beta-blocker with mild anti-alpha 1 adrenergic activity, offering therapeutic potential in various medical contexts. Its nonselective beta-blocking action results in decreased heart rate and cardiac output and induces splanchnic vasoconstriction, thereby reducing portal blood inflow and lowering portal pressure. This holds particular significance in addressing conditions like Portal Hypertensive Gastropathy (PHG), which is associated with chronic anaemia in cirrhosis patients. A key therapeutic aim in managing PHG is the reduction of portal pressure.